ArticleSynthetic and systems biotechnology2023
Improving solubility and copy number of taxadiene synthase to enhance the titer of taxadiene in
Article in Synthetic and systems biotechnology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 21 citations in OpenAlex.
- Metabolic engineering ofSynthetic and systems biotechnology · 2026Article
- Engineered microorganisms unlock a new era of diterpenoid biomanufacturing: recent advances and future perspectives.Bioresources and bioprocessing · 2026Review
- Toward Sustainable Paclitaxel Bioproduction: Plant Biology, Biosynthesis and Platform Engineering.Plants (Basel, Switzerland) · 2026Review
- Metabolic engineering of Yarrowia lipolytica targeting bottlenecks to boost D-Pantothenic acid biosynthesis.Bioresources and bioprocessing · 2026Article
- The biosynthesis and diversity of taxanes: From pathway elucidation to engineering and synthetic biology.Plant communications · 2025Review
- Transcriptome and Metabolome Analyses ofPlants (Basel, Switzerland) · 2025Article
- Dual distal insertions drive pimarane-to-miltiradiene rearrangement with enhanced enzymatic activity.Biodesign research · 2025Article
- Combinatorial metabolic engineering of Yarrowia lipolytica for high-level production of the plant-derived diterpenoid sclareol.Microbial cell factories · 2025Article
- Causal effect of gut microbiota metabolic pathways on CSAG1 expression in chondrosarcoma: a mendelian randomization analysis.BMC cancer · 2025Article
- Metabolic engineering of Saccharomyces cerevisiae for enhanced taxadiene production.Microbial cell factories · 2024Article
- Progress in the Metabolic Engineering ofBiodesign research · 2024Review
- Way to efficient microbial paclitaxel mass production.Synthetic and systems biotechnology · 2023Review
- Efficient production of 2'-fucosyllactose in unconventional yeastSynthetic and systems biotechnology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Taxadiene is an important precursor for the biosynthesis of highly effective anticancer drug paclitaxel, but its microbial biosynthesis yield is very low. In this study, we employed
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.